Literature DB >> 11527696

Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo.

M Fukushima1, A Fujioka, J Uchida, F Nakagawa, T Takechi.   

Abstract

A human tumour sub-line resistant to 5-fluorouracil (5-FU) was established by once a day and every 5, with at least 50 administrations of 5-FU to KM12C human colorectal xenografts in nude mice. KM12C tumours treated with 5-FU showed less sensitivity to 5-FU with an inhibition rate (IR) of 7.9%, while non-treated tumours were highly sensitive to 5-FU with an IR of 81.8%. To clarify the mechanism of 5-FU-resistance, the activities of various enzymes and gene expressions involved in the metabolism of 5-FU in both parental and 5-FU-treated KM12C tumours were measured. A 2- to 3-fold increase in thymidylate synthase (TS) activity and 4- to 5-fold decrease in ribonucleotide reductase (RNR) activity were observed in 5-FU-resistant KM12C tumours, while the activities of orotate phosphoribosyltransferase (OPRT) thymidine and uridine phosphorylases (TP,UP) and thymidine kinase (TK) were not markedly changed as a consequence of repeated treatment of KM12C tumours with 5-FU. The expression of TS mRNA was also amplified in accordance with the increased TS activity in a 5-FU-treated tumour sub-line (KM12C/5-FU) compared with that in parental tumours, but changed expressions of both RNR-R1 and RNA-R2 mRNA could not be detected in the 5-FU-resistant tumour sub-line compared with the parental tumours, suggesting possible post-transcriptional regulation of RNR. Moreover, RNR, in addition to TS and OPRT, seemed to be related to the inherent insensitivity to 5-FU in human cancer xenografts. From these results, it may be concluded that RNR activity is one of the acquired or inherent resistant factors, including TS, to 5-FU in human cancer xenografts in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11527696     DOI: 10.1016/s0959-8049(01)00174-5

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  23 in total

1.  Essential role of Tip60-dependent recruitment of ribonucleotide reductase at DNA damage sites in DNA repair during G1 phase.

Authors:  Hiroyuki Niida; Yuko Katsuno; Misuzu Sengoku; Midori Shimada; Megumi Yukawa; Masae Ikura; Tsuyoshi Ikura; Kazuteru Kohno; Hiroki Shima; Hidekazu Suzuki; Satoshi Tashiro; Makoto Nakanishi
Journal:  Genes Dev       Date:  2010-02-15       Impact factor: 11.361

2.  Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells.

Authors:  Ken Kurokawa; Toshihito Tanahashi; Tsutomu Iima; Yuta Yamamoto; Yoko Akaike; Kensei Nishida; Kiyoshi Masuda; Yuki Kuwano; Yoshiki Murakami; Masakazu Fukushima; Kazuhito Rokutan
Journal:  J Gastroenterol       Date:  2012-03-01       Impact factor: 7.527

3.  Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.

Authors:  Rebecca B Klisovic; William Blum; Zhongfa Liu; Zhiliang Xie; Cheryl Kefauver; Lenguyen Huynh; James A Zwiebel; Steven M Devine; John C Byrd; Michael R Grever; Kenneth K Chan; Guido Marcucci
Journal:  Leuk Lymphoma       Date:  2013-11-01

4.  Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402).

Authors:  Jing Jin; Min Huang; Huai-Ling Wei; Geng-Tao Liu
Journal:  World J Gastroenterol       Date:  2002-12       Impact factor: 5.742

5.  MEK2 regulates ribonucleotide reductase activity through functional interaction with ribonucleotide reductase small subunit p53R2.

Authors:  Chunmei Piao; Cha-Kyung Youn; Min Jin; Sang Pil Yoon; In-Youb Chang; Jung Hee Lee; Ho Jin You
Journal:  Cell Cycle       Date:  2012-08-16       Impact factor: 4.534

6.  In vivo 5FU-exposed human medullary thyroid carcinoma cells contain a chemoresistant CD133+ tumor-initiating cell subset.

Authors:  Lucia Kucerova; Lucia Feketeova; Zuzana Kozovska; Martina Poturnajova; Miroslava Matuskova; Radim Nencka; Pavel Babal
Journal:  Thyroid       Date:  2013-12-13       Impact factor: 6.568

Review 7.  Serine, glycine and one-carbon units: cancer metabolism in full circle.

Authors:  Jason W Locasale
Journal:  Nat Rev Cancer       Date:  2013-07-04       Impact factor: 60.716

8.  Combination therapy using oral S-1 and targeted agents against human tumor xenografts in nude mice.

Authors:  Mamoru Nukatsuka; Hitoshi Saito; Fumio Nakagawa; Hiroaki Tsujimoto; Kazuki Sakamoto; Sayaka Tsukioka; Junji Uchida; Mamoru Kiniwa; Takashi Kobunai; Teiji Takechi
Journal:  Exp Ther Med       Date:  2012-02-13       Impact factor: 2.447

9.  Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.

Authors:  Masanori Terashima; Hisataka Fujiwara; Akinori Takagane; Kaoru Abe; Takashi Irinoda; Tsutomu Nakaya; Hitoshi Yonezawa; Kenichi Oyama; Kazuyoshi Saito; Norio Kanzaki; Satoshi Ohtani; Tsuyoshi Nemoto; Yutaka Hoshino; Michihiko Kogure; Mitsukazu Gotoh
Journal:  Gastric Cancer       Date:  2003       Impact factor: 7.370

10.  Thymidylate synthase gene expression in primary tumors predicts activity of s-1-based chemotherapy for advanced gastric cancer.

Authors:  Hiroya Takiuchi; Shin-Ichiro Kawabe; Masahiro Gotoh; Ken-Ichi Katsu
Journal:  Gastrointest Cancer Res       Date:  2007-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.